Skip to main content

Immune DIREcted and Cancer-selective immunoTherapy

Objective

I-DireCT is a European Industrial Doctorate (EID) training network designed to provide training and carry out breakthrough research on the rapidly expanding and high impact field of cancer immunotherapy in a carefully integrated academic and inter-sectoral programme. Hereby, we aim to develop next-generation immunotherapeutics and deliver a set of early stage researchers uniquely qualified for a career in academia and/or industry.

Current immunomodulatory antibodies that target pivotal immune checkpoints have revolutionized the field of oncology. However, off-tumor activity limits their application. The objective of I-Direct is to address this issue by 1. developing innovative bispecific antibodies and immunocytokines with tumor-restricted immunostimulatory effects and 2. developing optimized delivery systems to ensure optimal timed release of bio-active drug. Hereto, I-DireCT combines state-of-the-art industrial design of nanotech-based drug formulations with innovative academic and industrial immunotherapeutic concepts into the next-generation of cancer immunotherapeutics.

At the core of I-DireCT is its training objective to offer a cutting-edge multidisciplinary training programme that will enable outstanding young scientists to generate breakthrough ideas and assume leading positions in academia and industry. This training programme includes an array of disciplines, ranging from biomedical sciences (e.g. immunology, antibody engineering) and physical sciences (e.g. chemistry, material science) to drug design & development.

Industrial partners are central to the programme and provide pivotal inter-sectoral expertise on how to translate scientific discoveries into commercial reality, with each ESR being appointed at an inter-sectoral partner for 18 months, as well as through additional secondments. Further, I-Direct will enable long-term multi-disciplinary research and fosters bilateral co-operations between academia and industry.

Coordinator

ACADEMISCH ZIEKENHUIS GRONINGEN
Net EU contribution
€ 922 291,25
Address
Hanzeplein 1
9713 GZ Groningen
Netherlands

See on map

Region
Noord-Nederland Groningen Overig Groningen
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Participants (4)

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Germany
Net EU contribution
€ 379 182,60
Address
Josef-schneider-strasse 2
97080 Wurzburg

See on map

Region
Bayern Unterfranken Würzburg, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
INOCURE SRO
Czechia
Net EU contribution
€ 469 743,12
Address
Politickych Veznu 935/13
11000 Praha

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Praha Hlavní město Praha
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
Surflay Nanotec GmbH
Germany
Net EU contribution
€ 505 576,80
Address
Max Planck Strasse 3
12489 Berlin

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Berlin Berlin Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
KAHR MEDICAL LTD
Israel
Net EU contribution
€ 256 181,45
Address
1 Kiryat Hadassah, Jbp Bldg
9109701 Jerusalem

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00